Lyka Labs' Q1 FY 2025-26 Quarterly Results

Result Summary

• Lyka Labs Ltd reported a 20.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.7%.
• Its expenses for the quarter were up by 8.7% QoQ and 12.1% YoY.
• The net profit decreased 147.4% QoQ and decreased 31.3% YoY.
• The earnings per share (EPS) of Lyka Labs Ltd stood at 0.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lyka Labs Ltd operates within the pharmaceutical industry, primarily focusing on the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is known for producing a variety of therapeutic products, which include formulations in dermatology, cardiology, and other specialty areas. As a player in the healthcare sector, Lyka Labs has been involved in various strategic initiatives to expand its product lines and improve its manufacturing capabilities. Recent developments in the company may include efforts to enhance their production facilities or to enter into strategic partnerships, though specific details are not available in the provided data.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Lyka Labs Ltd reported a total income of ₹33.66 crores. This represents a quarter-over-quarter increase of 20.0% compared to the fourth quarter of fiscal year 2025 (Q4FY25), where the total income was ₹28.06 crores. Year-over-year, there was a growth of 9.7% in total income when compared to the first quarter of fiscal year 2025 (Q1FY25), where the total income was ₹30.67 crores. These figures highlight the company's ability to increase its revenue both on a quarterly and yearly basis.

Profitability

For Q1FY26, Lyka Labs Ltd recorded a profit before tax of ₹1.35 crores. This is a significant turnaround from the previous quarter (Q4FY25), which saw a loss before tax of ₹1.63 crores, marking a quarter-over-quarter change of -182.8%. However, when compared to Q1FY25, there is a decline of 27.4% from a profit before tax of ₹1.86 crores. The company's profit after tax for Q1FY26 stood at ₹0.99 crores, which also reflects a recovery from a loss of ₹2.09 crores in Q4FY25, but a decrease of 31.3% from the profit of ₹1.44 crores in Q1FY25. Earnings per share for Q1FY26 was ₹0.30, improved from a loss per share of ₹3.80 in Q4FY25, but lower than ₹0.40 reported in Q1FY25, reflecting a year-over-year decrease of 25.0%.

Operating Metrics

Total expenses for Lyka Labs Ltd in Q1FY26 amounted to ₹32.30 crores, an increase of 8.7% from ₹29.71 crores reported in Q4FY25. On a year-over-year basis, the total expenses rose by 12.1% from ₹28.82 crores in Q1FY25. The tax expense for Q1FY26 was ₹0.36 crores, a reduction from ₹0.46 crores in Q4FY25, representing a quarter-over-quarter decrease of 21.7%. Compared to Q1FY25, where the tax expense was ₹0.57 crores, there is a year-over-year decrease of 36.8%. These changes in expenses and tax obligations are key metrics that influence the company's profitability and financial performance.